
Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer
The FDA has granted EBC-129, a novel antibody-drug conjugate (ADC), fast track designation for use in pancreatic ductal adenocarcinoma, according to a news release from The Experimental Drug Development Centre in Singapore.1 The fast track designation …